Cryosurgery: Clinical Trials

68 trials of Cryosurgery, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

34 completed, 11 unknown, 10 recruiting, 6 not yet recruiting. 68 Phase 2, 23 Phase 1, 6 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 268Completed 34, Unknown 11, Recruiting 10, Not yet recruiting 6, Terminated 3, Withdrawn 3, Active not recruiting 1
Phase 123Completed 19, Not yet recruiting 1, Terminated 1, Unknown 1, Withdrawn 1
Phase 36Completed 5, Withdrawn 1

Follow Cryosurgery: new trials by email Literature Review of Cryosurgery trials Research Report on Cryosurgery

Trials (filtered) newest first · largest first

All 68 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Cryoablation Combined With Anlotinib Plus TQB2868 in Patients With Advanced Intrahepatic Cholangiocarcinoma
Anlotinib, TQB2868 Injection, cryoablation - Intrahepatic Cholangiocarcinoma
Phase 2Not yet recruitingFudan University562026-10-012026-09-29
Study on Sequential Cryoablation, Relaforp Alpha, and Chemotherapy for Bile Duct Tumors
PD-1 and chemotherapy, cryoablation - Biliary Tract Cancer (BTC)
Phase 2RecruitingTianjin Medical University Cancer Institute and Hospital302026-10-012026-07-24
Cryoablation Combined With Hepatic Arterial Infusion of Iparomlimab and Tuvonralimab (QL1706), Intravenous Dacarbazine, and Oral Lenvatinib in Patients With Liver Metastases From Malignant Melanoma: a Single-arm, Phase II, Prospective Trial
Cryoablation, Iparomlimab and Tuvonralimab, Dacarbazine - Melanoma (Skin) Stage IV
Phase 2RecruitingSun Yat-sen University282026-10-012026-09-29
Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer.
QL1706 (Iparomlimab/Tuvonralimab), Lenvatinib, Cryoablation - Biliary Tract Cancer (BTC)
Phase 2Not yet recruitingFudan University1802026-09-202026-09-21
Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers
Cryoablation, Cryoablation combined with PD1 Inhibitor - Triple Negative Breast Cancer
Phase 1 / Phase 2Not yet recruitingTexas Tech University Health Sciences Center362026-03-012025-09-09
SEED-CRYO: Sequential 125I Seed Implantation Followed by Cryoablation vs Single-Modality Local Therapy in Unresectable Solid Tumors
Iodine-125 (125I) Seed Implantation, cryoablation, Sequential 125I Seed Implantation Followed by Cryoablation - Unresectable Solid Tumors
Phase 2Not yet recruitingLi Min1502026-02-012026-03-04
Lesion-Allocated Therapy for Multiple Metastases and Tumor-Zoned Treatment for Bulky Tumors: A Phase II Study of Iodine-125 Seed Implantation Combined With Cryoablation in High-Burden Metastatic Disease
Iodine-125 (125I) Seed Implantation (Low-Dose-Rate Brachytherapy), cryoablation, Lesion Allocation and Tumor Zoning Strategy - High-Burden Metastatic Solid Tumors
Phase 2Not yet recruitingLi Min902026-02-012026-02-27
Cryoablation Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy
Cryoablation, Dual-Function Antibody PD-1/CTLA-4 - Pancreatic Adenocarcinoma Locally Advanced
Phase 2RecruitingRuijin Hospital202025-12-152025-12-29
Cryoablation Combined With SHR-1701 Plus Famitinib in Patients With Advanced Intrahepatic Cholangiocarcinoma.
SHR-1701, Famitinib, Cryoablation - Advanced Intrahepatic Cholangiocarcinoma
Phase 2Not yet recruitingFudan University362025-09-012025-08-28
Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma
QL1706 (bispecific antibody targeting PD-1 and CLTA-4), Lenvatinib, cryoablation - Intrahepatic Cholangiocarcinoma (Icc)
Phase 2RecruitingFudan University562025-08-202025-08-12
Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-01)
Tislelizumab, Lenvatinib, cryoablation - Intrahepatic Cholangiocellular Carcinoma
Phase 2RecruitingFudan University922025-03-182025-04-06
Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma
Cryoablation, PD-1 antibody and bevacizumab - Carcinoma, Hepatocellular
Phase 2UnknownShanghai Zhongshan Hospital362024-07-312024-07-31
Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC
Toripalimab, Cryoablation - Non-small Cell Lung Cancer
Phase 2RecruitingShanghai Chest Hospital542024-04-022025-09-05
Cryoablation+Ipilimumab+Nivolumab in Melanoma
Ipilimumab, Nivolumab, Cryoablation - Metastatic Melanoma, Skin Cancer
Phase 2RecruitingMassachusetts General Hospital372023-09-232026-08-27
Cryoablation Combined with Tislelizumab Plus Lenvatinib in Previously Treated Solid Tumors (CASTLE-11)
Tislelizumab, Lenvatinib, Cryoablation - Solid Tumor, Adult
Phase 2RecruitingFudan University252023-09-132025-02-27
Study of Cryoablation and Nirogacestat for Desmoid Tumor
Nirogacestat, Cryoablation - Desmoid Tumor
Phase 2RecruitingNam Bui282023-08-152026-09-10
Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10)
Cryoablation, Tislelizumab, Lenvatinib - Hepatocellular Carcinoma
Phase 2UnknownFudan University252023-06-202023-06-27
Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Gastric Cancer Liver Metastasis (CASTLE-09)
Cryoablation, Tislelizumab, Lenvatinib - Gastric Cancer Metastatic to Liver
Phase 2UnknownFudan University252023-06-162023-06-27
Cryoablation Combined With Sintilimab Plus Lenvatinib in 1L Treatment of Advanced ICC (CASTLE-ICC-Chemo-free)
Cryoablation, Sintilimab, Lenvatinib - Advanced Intrahepatic Cholangiocarcinoma
Phase 2UnknownFudan University302023-04-282023-05-31
Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer (CASTLE-08)
Sintilimab, Lenvatinib, Cryoablation - Advanced Biliary Tract Cancer
Phase 2UnknownFudan University252023-03-232023-03-24

Showing 20 of 68. Sign in to see all of them.

Conditions studied

Carcinoma, Hepatocellular (8)  ·  Breast Neoplasms (7)  ·  Liver Neoplasms (6)  ·  Melanoma (6)  ·  Neoplasm Metastasis (5)  ·  Biliary Tract Neoplasms (4)  ·  Carcinoma, Non-Small-Cell Lung (4)  ·  Cholangiocarcinoma (4)  ·  Colorectal Neoplasms (4)  ·  Sarcoma (4)  ·  Carcinoma, Renal Cell (3)  ·  Kidney Neoplasms (3)  ·  Lung Neoplasms (3)  ·  Osteosarcoma (2)  ·  Ovarian Neoplasms (2)

Sponsors

Fuda Cancer Hospital, Guangzhou (21)  ·  Fudan University (13)  ·  Mirror Biologics, Inc. (3)  ·  Li Min (2)  ·  Massachusetts General Hospital (2)  ·  Mayo Clinic (2)  ·  National Cancer Institute (NCI) (2)  ·  Rampart Health, L.L.C. (2)  ·  Sun Yat-sen University (2)  ·  Alliance for Clinical Trials in Oncology (1)  ·  Barbara Ann Karmanos Cancer Institute (1)  ·  Children's National Research Institute (1)  ·  Eastern Cooperative Oncology Group (1)  ·  Kristen Ganjoo (1)  ·  M.D. Anderson Cancer Center (1)

Countries

China (42)  ·  United States (20)  ·  Canada (2)  ·  Chile (1)  ·  India (1)  ·  Israel (1)  ·  Singapore (1)  ·  Thailand (1)

Top investigators

Jibing Chen, MD, PhD (7)  ·  Peng Wang, MD (5)  ·  Guifeng Liu, PhD (3)  ·  Jibing Chen, PhD (3)  ·  Min Li (2)  ·  Peng Wang (2)  ·  Tim F Greten, M.D. (2)  ·  AeRang Kim, MD, PhD (1)  ·  Anil Kapoor, MD (1)  ·  Brenda L Gallie, MD (1)  ·  Brian Van Tine, M.D., Ph.D. (1)  ·  David G Bostwick, M.D., M.B.A. (1)  ·  David G Bostwick, M.D.,M.B.A. (1)  ·  Dr. Michael Har-Noy (1)  ·  Elise Heon, MD (1)

Results publications

PMID 18054441, PMID 18565579, PMID 18834631, PMID 21123824, PMID 22075702, PMID 27221361, PMID 27816492, PMID 28508945, PMID 28923358, PMID 29487221, PMID 30578687, PMID 30688989, PMID 38205877, PMID 39965889, PMID 41176543

NIH funding

P30CA022453 (1), P50CA097274 (1), R01CA219960 (1)